Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: Results of a controlled, randomized efficacy trial

Journal of Infectious Diseases

Volumn 210, Issue 4, 2014, Pages 545-557

  Nolan, Terry ^a,b   Roy Ghanta, Sumita ^c   Montellano, May ^e   Weckx, Lily ^h   Ulloa Gutierrez, Rolando ^k   Lazcano Ponce, Eduardo ^l   Kerdpanich, Angkool ^p   Safadi, Marco Aurélio Palazzi ^i,j   Cruz Valdez, Aurelio ^l   Litao, Sandra ^f   Lim, Fong Seng ^r   De Los Santos, Abiel Mascareñas ^m   Weber, Miguel Angel Rodriguez ⁿ   Tinoco, Juan Carlos ^o   Mezerville, Marcela Hernandez De ^k   Faingezicht, Idis ^k   Kosuwon, Pensri ^q   Lopez, Pio ^s   Borja Tabora, Charissa ^g   Li, Ping ^c   Durviaux, Serge ^t   Fries, Louis ^d   Dubin, Gary ^c   Breuer, Thomas ^t   Innis, Bruce L ^c   Vaughn, David W ^t   more..

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c GLAXOSMITHKLINE   (United States)

^d NOVAVAX INC   (United States)

^e Department of Pediatrics Mary Chiles General Hospital   (United States)

^f De La Salle Health Sciences Institute   (Philippines)

^g Department of Health Research Institute for Tropical Medicine ^*  (Philippines)

^h FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^j Clinical Microbiology Section   (Brazil)

^k Inst Costarricense Invest Clinicas   (Costa Rica)

^l INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^m UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

ⁿ INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^o Hospital General de Durango   (Mexico)

^p PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^q KHON KAEN UNIVERSITY   (Thailand)

^r NATIONAL HEALTHCARE GROUP POLYCLINICS   (Singapore)

^s Centro de Estudios en Infectologia Pediatrica   (Colombia)

^t GSK   (Belgium)

more..

Author keywords

Children; Efficacy; H1N1; Influenza virus; Pandemic influenza vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; IMMUNOLOGICAL ADJUVANT AS03; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ACUTE GLOMERULONEPHRITIS; ALOPECIA AREATA; APPENDICITIS; ARTICLE; ASTHMA; BRONCHITIS; CHILD; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; FEBRILE CONVULSION; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; GLOMERULONEPHRITIS; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGENICITY; IMMUNOLOGICAL MONITORING; IMMUNOPROPHYLAXIS; IMMUNOREACTIVITY; INFANT; INFECTION PREVENTION; INFECTION RATE; INFLUENZA VACCINATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE SMEAR; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RELATIVE VACCINE EFFICACY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SEROCONVERSION; SINGLE BLIND PROCEDURE; SURVIVAL RATE; SURVIVAL TIME; THROAT CULTURE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING;

CHILDREN; EFFICACY; H1N1; INFLUENZA VIRUS; PANDEMIC INFLUENZA VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PROSPECTIVE STUDIES; VACCINATION;

EID: 84905565035     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu173     Document Type: Article

References (32)

1. Viboud C, Boëlle P-Y, Cauchemez S, et al. Risk factors of influenza transmission in households. Br J Gen Pract 2004; 54: 684-9.
2. Janjua NZ, Skowronski DM, Hottes TS, et al. Transmission dynamics and risk factors for pandemic H1N1-related illness: outbreak investigation in a rural community of British Columbia, Canada. Influenza Other Respi Viruses 2012; 6: e54-62.
3. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12: 687-95.
4. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; CD004879.
5. Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365: 1406-16.
6. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340: c2649.
7. Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012; 11: 349-66.
8. McElhaney JE, Beran J, Devaster J-M, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013; 13: 485-96.
9. Kendal A, Pereira M, Skehel J. Hemagglutination inhibition. Concepts and procedures for laboratory-based influenza surveillance. Atlanta, Georgia: Centers for Disease Control and Prevention and Pan-American Health Organization, 1985.
10. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103: 163-71.
11. Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29: 2461-73.
12. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004; 103: 133-8.
13. Beyer WE, Palache AM, Baljet M, Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989; 7: 385-94.
14. WHO | FluNet - CHARTS. WHO. Available at: http: //www.who.int/ influenza/gisrs-laboratory/flunet/charts/en/index.html. Accessed 21 June 2012.
15. Jain VK, Rivera L, Chandrasekaran V, et al. Efficacy of an inactivated quadrivalent influenza vaccine candidate in children 3-8 years of age [abstract 1793]. Presented at IDWeek Scientific Meeting; October 17-21, 2012; San Diego, CA.
16. Van Buynder PG, Dhaliwal JK, Van Buynder JL, et al. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respi Viruses 2010; 4: 171-8.
17. Skowronski DM, Janjua NZ, De Serres G, et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 2011; 342: c7297.
18. Mahmud S, Hammond G, Elliott L, et al. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study. Vaccine 2011; 29: 7975-81.
19. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster J-M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28: 1740-5.
20. Carmona A, Omeñaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010; 28: 5837-44.
21. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012; 7: e33536.
22. Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013; 346: f794.
23. Dauvilliers Y, Arnulf I, Lecendreux M, et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 2013; 136: 2486-96.
24. Heier MS, Gautvik KM, Wannag E, et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med 2013; 14: 867-71.
25. Szakács A, Darin N, Hallböök T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 2013; 80: 1315-21.
26. Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31: 1246-54.
27. Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010 Final Report of National Narcolepsy Study Steering Committee. 2012. Available at: http: //healthupdate.gov. ie/wp-content/uploads/2012/04/Final-Report-of-National-Narcolepsy- Study-Steering-Committee-latest1.pdf. Accessed 31 July 2013.
28. European Centre for Disease Prevention and Control. Narcolepsy in association with pandemic influenza vaccination. A multi-country European epidemiological investigation. Stockholm: ECDC; 2012 September Report No. Stockholm: ECDC, September 2012.
29. Registry study confirms increased risk of narcolepsy after vaccination with Pandemrix in children and adolescents and shows an increased risk in young adults - Medical Products Agency, Sweden. Available at: http: //www.lakemedelsverket.se/english/All-news/NYHETER-2013/ Registry-study- confirms-increased-risk-of-narcolepsy-after-vaccinationwith- Pandemrix-in-children-and-adolescents-and-shows-an-increasedrisk- in-young-adults/. Accessed 31 July 2013.
30. Barker CIS, Snape MD. Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis 2013; 14: 227-38.
31. Pitkänen M. Increased risk of narcolepsy observed also among adults vaccinated with Pandemrix in Finland. 2013. Available at: http: //www. thl.fi/en-US/web/en/pressrelease?id=33516. Accessed 31 July 2013.
32. De la Herrán-Arita AK, Kornum BR, Mahlios J, et al. CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med 2013; 5: 216ra176.